Publication | Closed Access

Activity of single-agent melphalan 220–300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma

Hematological MalignancyLymphoid NeoplasiaHodgkin LymphomaMedicineImmunologyTumor ImmunityHematologyImmune SurveillanceAmifostine CytoprotectionSingle-agent Melphalan 220–300OncologyRadiation OncologyHealth Sciences